Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Total 13F shares
-
18,942,451
-
Share change
-
-4,040,186
-
Total reported value
-
$40,725,621
-
Put/Call ratio
-
1327%
-
Price per share
-
$2.15
-
Number of holders
-
64
-
Value change
-
-$19,620,718
-
Number of buys
-
19
-
Number of sells
-
32
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2024
As of 30 Sep 2024,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,942,451 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Siren, L.L.C., ADAGE CAPITAL PARTNERS GP, L.L.C., Samsara BioCapital, LLC, Point72 Asset Management, L.P., Flagship Pioneering Inc., Avidity Partners Management LP, VANGUARD GROUP INC, Deep Track Capital, LP, and Opaleye Management Inc..
This page lists
64
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.